May 20, 2022--Shanghai BRL Medicine Co., Ltd. (hereinafter referred to as “BRL Medicine”) announces the appointment of Dr. Zheng Biao as the Senior partner of BRL Medicine, as the Chief Executive Officer (CEO) of the company with overall responsibility for the operation and management of the company. Dr. Zheng has more than 30 years of experience in the pharmaceutical industry, especially in the field of immunotherapy (macromolecular antibody, cell therapy, etc.). He has deep insights and experience in drug development, international medical environment, market access and commercialization.

Dr. Zheng has extensive industrialization experience, including major international pharmaceutical companies and domestic biopharmaceutical companies. Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. In 2015, he joined Johnson & Johnson as global vice president in Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific. Before joining BRL Medicine Inc., he joined IASO Biotherapeutics as the chief scientific officer 2020.

 Dr. Biao Zheng

Dr. Biao Zheng graduated from the medical department of the Medical College of Zhejiang University with a bachelor's degree in clinical medicine. He received his MS and PhD in Immunology from Fudan University School of Medicine and King’s College, University of London, respectively. Dr.  Zheng has taught at the University of Maryland School of Medicine and Duke University Medical Center. Subsequently, he served as a tenured professor in the Department of Pathology and Immunology at Baylor College of Medicine. Dr. Zheng has published a number of papers in the world top journals such as Nature and Science.